Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.13024 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Pedro H Reis-Barbosa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Biomedical Center, The University of the State of Rio de Janeiro, Rio de Janeiro, …. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dipeptidyl-Peptidase IV Inhibitors, Mice, Inbred C57BL, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Background
Monotherapy to treat obesity‐associated liver insult is limited.
Objectives
In diet‐induced obese mice showing metabolic dysfunction‐associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i, empagliflozin, E), dipeptidyl peptidase‐4 inhibitor (DPP4i, linagliptin, L), and glucagon‐like peptide type 1 receptor agonist (GLP1RA, dulaglutide, D).
Methods
Male 3‐month‐old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high‐fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D ( n = 10/group).
Results
HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed lower glucose intolerance (−60%), insulin (−61%), insulin resistance (−46%), TAG (−61%), and steatosis (−58%), and HF E + D showed lower glucose intolerance (−71%), insulin (−58%), insulin resistance (−62%), TAG (−61%), and steatosis (−82%). The principal component analysis (PCA) placed the HF group and the HF E + D group on opposite sides, while the HF E + L group was placed between C and HF E + D.
Conclusion
PCA separated the groups considering the metabolism‐related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treating obesity and MASLD. However, the combination of SGLT2i and GLP1RA showed more potent beneficial effects on MASLD than SGLT2i and DPP4i and, therefore, should be the recommended combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Morphometry, Metabolism and Cardiovascular Diseases, Biomedical Center, The University of the State of Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Pedro H Reis-Barbosa, Carlos A Mandarim-de-Lacerda
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
Zitieren
APA
Reis-Barbosa, P. H., & Mandarim-de-Lacerda, C. A. (2024). Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD). Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.13024
Vancouver
Reis-Barbosa PH, Mandarim-de-Lacerda CA. Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD). Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.13024
BibTeX
@article{ReisBarbosa2024,
author = {Reis-Barbosa, Pedro H and Mandarim-de-Lacerda, Carlos A},
title = {Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.13024}
}
EUVIMED